CLEAR

Confluera delivers real-time infrastructure-wide cyber kill chain tracking and response by leveraging Continuous Attack Graph technology to deterministically stop and remediate cyberthreats in real-time. The company's platform combines behavioral analytics and ML-powered anomaly detection to identify and intercept cyberattacks across multi-cloud and hybrid environments, reducing alert noise by up to 98% while accelerating incident response 10x. Founded by cybersecurity veterans and backed by leading venture capitalists, Confluera has developed the industry's first Real-time Attack Interception and Defense Platform. The solution automatically tracks every movement across cloud infrastructure, connecting the dots between users, processes, IAM roles, and control plane resources to provide complete attack visualization. In March 2023, Confluera was acquired by XM Cyber, extending its run-time protection capabilities on cloud workloads and strengthening its position in the CNAPP market.

In 2023, a group of visionary scientists and investors recognized that drug discovery remained an expensive, time-consuming process with high failure rates. Despite advances in AI, the pharmaceutical industry was still struggling to translate computational insights into viable medicines. This realization sparked the creation of Xaira Therapeutics - co-founded and incubated by ARCH Venture Partners and Foresite Labs - to build an integrated biotechnology company that would truly harness the transformative power of artificial intelligence for drug discovery. Built on the groundbreaking protein design work of Nobel Laureate Dr. David Baker and his team at the University of Washington's Institute for Protein Design, Xaira brings together advanced AI research, expansive data generation, and robust therapeutic product development. The company emerged from stealth mode in 2024 with over $1 billion in funding, ready to revolutionize how we treat disease by making predictions about the right biology to target, the best therapeutics to modulate those targets, and the patients who will benefit most. With offices in South San Francisco, Seattle, and London, Xaira is shifting drug discovery from an empirical science to a precise engineering discipline.

Roke is a sovereign UK defence and national security company founded in 1956, originally with 28 engineers. Now a subsidiary of Chemring Group PLC, it employs more than 850 people - nearly 60% of them engineers - and delivers intelligence and engineering solutions to government and military clients across defence, national security, and critical infrastructure. The company's technical work spans six broad capability areas: Advanced AI and Analytics, Autonomy and Robotics, Cyber and Secure Communications, Electromagnetic Spectrum Operations, Intelligence and Insight, and Specialised Sensors and Effectors. Its product portfolio includes CORTEXA GUARDIAN for counter-UAS operations, Crucible for geopolitical risk intelligence, EM-Vis for electromagnetic spectrum management, and Strix for automated binary analysis. Roke's engineering-heavy workforce operates across domains that include sensors, communications, cyber security, and artificial intelligence, with a stated focus on protecting UK interests at home and abroad - including troops, borders, and critical national infrastructure. The company reports double-digit revenue growth.

Boeing Intelligence & Analytics (BI&A) serves the Intelligence Community with innovation and vision through advanced analytics and intelligence solutions. A fully owned subsidiary of The Boeing Company under Boeing Defense, Space & Security, BI&A delivers seamless solutions ready for tomorrow's challenges by integrating cutting-edge engineering practices with rigorous cybersecurity measures. The company maintains top-tier technical talent and industry expertise in software engineering, systems integration and development, rapid prototyping, and project leadership to support critical national security missions. Every day, Boeing Intelligence & Analytics supports global missions by building and delivering intelligence, analytics, and cyber solutions that enable users to advance national security. From hardware and software engineering solutions to analytics that keep this nation safe, BI&A integrates products and people to keep mission partners ahead of evolving global and cyber threats. The company has provided customers with the tools needed to counter evolving global and cyber threats and to improve wartime decision-making, all while cultivating a healthy work-life balance for its highly-skilled workforce.

Accelya is a global software company serving the airline industry, with a client base of more than 200 airlines and over 40 years of operating history. Backed by Vista Equity Partners, the company employs more than 2,900 people across 10 offices worldwide. Its core offering is an open, modular, cloud-native platform designed to manage the full commercial stack for airlines - from offer management and retailing through to revenue accounting and transaction processing. The company's flagship product, FLX ONE, processes more than $100 billion in transactions annually. The platform's architecture is built to allow airlines to adopt components independently rather than committing to a monolithic system, giving carriers flexibility in how they modernise their commercial operations. Accelya's technical work spans several domains, including offer management, airline retailing, revenue accounting, and enterprise-scale transaction infrastructure. The company positions its platform as cloud-native and modular, with development priorities centred on giving airlines greater control over their retailing and commercial capabilities. Engineering and product teams work on systems that operate at significant scale - processing billions of dollars in transactions for some of the world's largest carriers.

Invivoscribe is a global leader in precision oncology diagnostics, dedicated to improving lives with standardized molecular testing solutions. For over 30 years, the company has pioneered the international standardization of molecular and flow cytometry testing, expanding access to advanced cancer therapies worldwide. Invivoscribe develops and manufactures a comprehensive portfolio of molecular assays, reagents, controls, and bioinformatics tools under ISO 13485 design control, supporting more than 700 clinical laboratories in over 160 countries. The company's Streamlined CDx (companion diagnostic) model accelerates the development of novel therapeutics, enabling personalized approaches to patient care. Invivoscribe's products consistently surpass industry and regulatory standards, playing a crucial role in identifying, stratifying, and monitoring hematologic cancers. Through its subsidiary, the Laboratory for Personalized Molecular Medicine (LabPMM), Invivoscribe offers extensive clinical diagnostic and biopharma services, providing globally standardized flow cytometry and molecular testing services for pharmaceutical and healthcare organizations across the U.S., Europe, and Asia.